Calories from carbohydrates: Energetic contribution of the carbohydrate moiety of rebeccamycin to DNA binding and the effect of its orientation on topoisomerase I inhibition

Chemistry and Biology

Volumn 6, Issue 5, 1999, Pages 277-286

  Bailly, Christian ^a   Qu, Xiaogang ^b   Graves, David E ^b   Prudhomme, Michelle ^c   Chaires, Jonathan B ^b  

^a CENTRE OSCAR LAMBRET   (France)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

Carbohydrate DNA recognition; Indolocarbazole; Rebeccamycin; Stereospecificity; Topoisomerase I

Indexed keywords

ESCHERICHIA COLI;

EID: 0033133944     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(99)80073-8     Document Type: Article

References (44)

1. 1. Ruegg, U.T. & Burgess, G.M. (1989). Staurosporine, K-252a, and UCN-01 : potent but nonspecific inhibitors of protein kinase. Trends Pharmacol. Sci. 10, 218-220.
2. 2. Akinaga, S., Gomi, K., Morimoto, M., Tamaoki, T. & Okabe, M. (1991). Antitumor activity of UCN-01, a selective inhibitor of protein kinase C, in murine and human tumor models. Cancer Res. 51, 4888-4892.
3. 3. Shao, R.G., Cao, C.X., Shimizu, T., O'Connor, P.M., Kohn, K.W. & Pommier, Y. (1997). Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res. 57, 4029-4035.
4. 4. Prudhomme, M. (1997). Indolocarbazoles as anti-cancer agents. Curr. Pharm. Des. 3, 265-290.
5. 5. Nettleton, D.E., Doyle, T.W., Krishnan, B., Matsumoto G.K. & Clardy, J. (1985). Isolation and structure of rebeccamycin - a new antitumor antibiotic from Nocardia aerocolonigenes. Tetrahedron Lett. 26,4011-4014.
6. 6. Bush, J.A., Long, B.H., Catino, J.J., Bradner, W.T. & Tomita, K. (1987). Production and biological activity of rebeccamycin, a novel antitumor agent. J. Antibiotics 40, 668-678.
7. 7. Matson, J.A., et al. & Patel, M. (1989). AT2433-A1, AT2433-A2, AT2433-B1 and AT2433-B2, novel antitumor antibiotic compounds produced by Actinomadura malliaura. J. Antibiot. 42, 1547-1555.
8. 8. Yamashita, Y., Fujii, N., Murakata, C., Ashizawa, T., Okabe, M. & Nakano, H. (1992). Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 31, 12069-12075.
9. 9. Rodrigues-Pereira E., et al. & Fabbro, D. (1996). Structure-activity relationships in a series of substituted indolocarbazoles: topoisomerase I and protein kinase C inhibition and antitumoral and antimicrobial properties. J. Med. Chem. 39, 4471-4477.
10. 10. Bailly, C., Riou, J.F., Colson, P., Moussier, C., Rodrigues-Pereira, E. & Prudhomme, M. (1997). DNA cleavage by topoisomerase I in the presence of indolocarbazole derivatives of rebeccamycin. Biochemistry 36, 3917-3929.
11. 11. Yoshinari, T., et al., & Okura, A. (1993). Induction of topoisomerase-I-mediated DNA cleavage by a new indolocarbazole, ED-110. Cancer Res. 53, 490-494.
12. 12. Yoshinari, T., et al., & Nishimura, S. (1995). Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7-(6H)-dione (NB-506): induction of topoisomerase-I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res. 55, 1310-1315.
13. 13. Arakawa, H., et al., & Nishimura, S. (1995). Novel indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)-5H-indolo[2,3-a]pyrrolo-[3,4-c]carbazole-5,7-(6H)-dione (NB-506): its potent antitumor activities in mice. Cancer Res. 55, 1316-1320.
14. 14. Ohe, Y., et al., & Sasaki, Y. (1997). Phase I and pharmacology study of 5-day infusion of NB-506. Proc. ACSO 16, 199a.
15. 15. Saijo, N. (1998). New chemotherapeutic agents for the treatment of non-small cell lung cancer. Chest 113, 1 7S-25S.
16. 16. Bailly, C., Colson, P., Moussier, C., Rodrigues-Pereira, E., Prudhomme, M. & Waring, M.J. (1998). Recognition of specific sequences in DNA by a topoisomerase I inhibitor derived from the antitumor drug rebeccamycin. Mol. Pharmacol. 53, 77-87.
17. 17. Record, M.T., Anderson, C.F. & Lohman, T.M. (1978). Thermodynamic analysis of ion effects on the binding and conformational equilibria of proteins and nucleic acids: the role of ion association or release, screening, and ion effects on water activity. Quart. Rev. Biophys. 11, 103-178.
18. 18. Friedman, R.A. & Manning, G.S. (1984). Polyelectrolyte effects on site-binding equilibria with application to the intercalation of drugs into DNA. Biopolymers 23, 2671-2714.
19. 19. Chaires, J.B., Priebe, W., Graves, D.E. & Burke, T.G. (1993). Dissection of the free energy of anthracycline antibiotic binding to DNA: electrostatic contributions. J. Am. Chem. Soc. 115, 5360-5364.
20. 20. Record, M.T., Jr. & Spolar. R. (1990). Some thermodynamic principles of nonspecific and site-specific protein-DNA interactions. The Biology of Nonspecific DNA-Protein Interactions. (Revzin, A., ed.). pp. 33-69, CRC Press, Boca Raton, FL.
21. 21. Record, M.T., Jr., Ha, J.H. & Fisher, M.A. (1991). Analysis of equilibrium and kinetic measurements to determine thermodynamic origins of stability and specificity and mechanism of formation of site-specific complexes between proteins and helical DNA. Methods Enzymol. 208, 291-343.
22. 22. Le Pecq, J.B. & Paoletti, C. (1967). A fluorescent complex between ethidium bromide and nucleic acids. J. Mol. Biol. 27, 87-106.
23. 23. Suh, D. & Chaires, J.B. (1995). Criteria for the mode of binding of DNA binding agents. Bioorg. Med. Chem. 3, 723-728
24. 2+ with DNA: a calorimetric and equilibrium binding study. J. Am. Chem. Soc. 117, 4788-4796.
25. 25. Moreau, P., et al., & Aubertin, A.M. (1998). Syntheses and biological evaluation of indolocarbazoles, analogs of rebeccamycin, modified at the imide heterocycle. J. Med. Chem. 41, 1631-1640.
26. 26. Bailly, C. & Waring, M.J. (1997). Diethylpyrocarbonate and osmium tetroxide as probes for drug-induced changes in DNA conformation in vitro. In Drug-DNA Interactions: Methods, Case Studies, and Protocols. Methods in Molecular Biology, volume 90. (Fox, K.R., ed). pp. 51-79, Humana Press, Totowa, NJ.
27. 27. Chaires, J.B., Satyanarayana, S., Suh, D., Fokt, I., Przewloka, T. & Priebe, W. (1996). Passing the free energy of anthracycline antibiotic binding to DNA. Biochemistry 35, 2047-2053.
28. 28. Chaires, J.B. (1996). Dissecting the free energy of drug binding to DNA. Anti-Cancer Drug Des. 11, 569-580.
29. 29. Kahne, D. (1995). Strategies for the design of minor groove binders: a re-evaluation based on the emergence of site-selective carbohydrate binders. Chem. Biol. 2, 7-12.
30. 30. Sears, P. & Wong, C.H. (1996). Intervention of carbohydrate recognition by proteins and nucleic acids. Proc. Natl Acad. Sci. USA 93, 12086-12093.
31. 1 oligosaccharide with duplex DNA. J. Am. Chem. Soc. 114, 7555-7557.
32. 32. Paloma, L.G., Smith, J.A., Chazin, W.J. & Nicolaou, K.C. (1994). Interaction of calicheamicin with duplex DNA: role of the oligosaccharide domain and identification of multiple binding modes. J. Am. Chem. Soc. 116, 3697-3708.
33. 33. Ikemoto, N., Kumar, R.A., Ling, T.T., Ellestad, G.A., Danishefsky, S.J. & Patel, D.J. (1995). Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove. Proc. Natl Acad. Sci. USA 92, 10506-10510.
34. 34. Chatterjee, M., Smith, P.J. & Townsend, C.A. (1996). The role of the aminosugar and helix binding in the thiol-induced activation of calicheamicin for DNA cleavage. J. Am. Chem. Soc. 118, 1938-1948.
35. 1-DNA complex. J. Mol. Biol. 265, 187-201.
36. 1-DNA complex. J. Mol. Biol. 265, 173-186.
37. 37. Liu, C., et al., & Vogt, P.K. (1996). Sequence-selective carbohydrate-DNA interaction: dimeric and monomeric forms of calicheamicin oligosaccharide interfere with transcription factor function. Proc. Natl Acad. Sci. USA 93, 940-944.
38. 38. Ho, S.N., Boyer, S.H., Schreiber, S.L., Danishefsky, S.J. & Crabtree, G.R. (1994). Specific inhibition of formation of transcription complexes by a calicheamicin oligosaccharide: a paradigm for the development of transcriptional antagonists. Proc. Natl Acad. Sci. USA 91, 9203-9207.
39. 39. Myers, A.G., Kort, M.E. & Hammond, M. (1997). A comparison of DNA cleavage by neocarzinostatin chromophore and its aglycone: evaluating the role of the carbohydrate residue. J. Am. Chem. Soc. 119, 2965-2972.
40. 40. Jiang, L., Suri, A.K., Fiala, R. & Patel, D.J. (1997). Saccharide-RNA recognition in an aminoglycoside antibiotic-RNA aptamer complex. Chem. Biol. 4, 35-50.
41. 41. Wang, A.H.J., Ughetto, G., Quigley, G.J. & Rich, A. (1987). Interactions between an anthracycline antibiotic and DNA: molecular structure of daunomycin complexed to d(CpGpTpApCpG) at 1.2 Å resolution. Biochemistry 26, 1152-1163.
42. 42. Frederick, C. A., et al., & Wang, A. H.-J. (1990). Structural comparison of anticancer drug-DNA complexes: adriamycin and daunomycin. Biochemistry 29, 2538-2549.
43. 43. Chaires, J.B. (1990). Biophysical chemistry of the daunomycin-DNA interaction. Biophys. Chem. 35, 191-202.
44. 44. Anizon, F., et al., & Meyer, T. (1997). Syntheses and biological activity (topoisomerases inhibition, antitumoral and antimicrobial properties) of rebeccamycin analogs bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group. J. Med. Chem. 40, 3456-3465.